Blood tests may help identify people at risk of developing inflammatory bowel disease (IBD) up to a decade before symptoms appear, according to new research that highlights the potential for earlier detection and intervention.
The study suggests that specific patterns of antibodies in the blood may reveal early signs of changes in the immune system long before a person receives a diagnosis. Researchers say the findings could eventually help doctors recognize individuals at increased risk before significant damage to the digestive tract occurs.
Crohn’s disease and ulcerative colitis are the two main forms of inflammatory bowel disease. Both conditions involve chronic inflammation of the digestive tract and can cause symptoms such as abdominal pain, persistent diarrhea, fatigue and other digestive complications.
Diagnosis often happens after symptoms become noticeable, meaning inflammation and tissue damage may already have developed. However, the new findings suggest that biological changes associated with these conditions may begin years earlier.
According to The Guardian, researchers believe that monitoring antibody patterns could eventually provide a way to identify these early warning signs.
“For a long time, we have only been able to treat inflammatory bowel disease after the damage has occurred, and for many people, that is too late,” said Dr. Arno Bourgonje, a researcher affiliated with University Medical Center Groningen in the Netherlands and the Icahn School of Medicine at Mount Sinai in New York.
Bourgonje explained that the disease process may begin long before symptoms emerge, leaving detectable signals in the immune system. However, he cautioned that the approach cannot yet reliably predict whether an individual will eventually develop the condition.
What Researchers Discovered in Blood Samples
The research team examined 2,000 blood samples collected from 500 members of the United States military. Among the participants, 200 later developed Crohn’s disease, another 200 developed ulcerative colitis, and 100 did not develop either condition.
Researchers focused on antibodies, proteins produced by the immune system in response to potential threats, including bacteria, viruses and other substances. Some antibodies can also target the body’s own proteins.
By examining these immune responses, the team sought to identify patterns associated with the future development of inflammatory bowel disease.
Epstein-Barr Virus Linked to Crohn’s Disease Risk
Among participants who later developed Crohn’s disease, researchers found more frequent antibody responses against the Epstein-Barr virus (EBV).
EBV is a common virus that can cause infectious mononucleosis, sometimes known as glandular fever. Most people encounter the virus during their lifetime, and it can remain in the body after the initial infection.
The differences in antibody patterns were detectable as much as 10 years before participants received a Crohn’s disease diagnosis. Researchers also observed stronger signals among individuals who later developed more severe forms of the disease.
These findings could help scientists better understand how immune responses and environmental factors may be associated with the development of Crohn’s disease.
However, the study does not establish that Epstein-Barr virus directly causes Crohn’s disease. The observed association requires further investigation before researchers can determine its precise significance.
Ulcerative Colitis Showed a Different Antibody Pattern
Participants who later developed ulcerative colitis displayed a different pattern of immune activity, including antibodies directed against a protein produced by the body itself.
This distinction is important because Crohn’s disease and ulcerative colitis share several symptoms but can differ in how they affect the digestive tract and how they respond to treatment.
Identifying separate antibody signatures could eventually help researchers develop more targeted approaches to assessing the risk of each condition.
Nevertheless, scientists will need to establish how accurately these patterns distinguish people who will develop the diseases from those who will remain healthy.
Could Early Detection Change the Treatment of IBD?
The possibility of detecting inflammatory bowel disease years before symptoms appear could represent an important step toward more personalized healthcare.
If future studies confirm the findings, blood-based screening methods might help doctors identify people who could benefit from closer monitoring or additional testing. Earlier identification could also create opportunities to investigate whether interventions can delay disease progression or reduce the risk of intestinal damage.
Professor James Lindsay, a gastroenterologist who was not involved in the research, said the findings offer valuable insights into Crohn’s disease and ulcerative colitis and could contribute to identifying people at increased risk.
However, he cautioned that these methods remain research tools and are not yet ready for routine use in hospitals.
The study’s findings were published in the scientific journal Gut and presented at a European gastroenterology conference in Barcelona. Researchers emphasized that the results must be validated in additional populations before the approach can be considered for wider clinical use.
What Happens Next?
Further research will be needed to determine whether antibody patterns can reliably predict who will develop inflammatory bowel disease, how early these signals can be detected and whether they can help doctors make better treatment decisions.
Scientists must also establish how the approach performs across different populations, since the initial study involved members of the US military rather than a broadly representative group of people.
Marinanne Radcliffe, a scientist commenting on the findings, expressed hope that identifying people at risk earlier could eventually allow treatment to begin before substantial intestinal damage occurs.
In the longer term, researchers hope that better understanding of the early stages of inflammatory bowel disease could lead to strategies that delay or potentially prevent the onset of symptoms in some individuals.
For now, the findings offer a promising research direction rather than a clinically established prediction test. Their greatest potential may lie in helping scientists understand what happens inside the body years before Crohn’s disease or ulcerative colitis becomes apparent.
